CD163, an M2 marker, is strongly linked to immunosuppressive functions and poor prognosis in cancers such as pancreatic cancer and melanoma (25) Depletion or functional blockade of CD163+ TAMs has been shown to enhance T-cell–mediated immunity and improve responses to PD−1 blockade in preclinical studies (81). This evidence concerns the gene CD163 and melanoma.